A total of 118,340 SAS-B approvals were issued by the Therapeutic Goods Administration (TGA) in 2022, down from 122,011 in 2021 – the first time the figure has fallen year-on-year. 

However, following TGA reforms introduced in November 2021, prescribers now require fewer approvals, even though they may be prescribing more medicine.

One industry observer told Cannabiz the number of medicinal cannabis patients has likely doubled or even tripled in 2022, but the streamlined system means SAS-B and Authorised Prescriber data after November 2021 cannot be directly compared to historical data.

December saw just 8,090 approvals, surpassing January’s low of 8,684.

Prior to launching Cannabiz, Martin was co-founder and CEO of Asia-Pac’s leading B2B media and marketing information brand Mumbrella, overseeing its sale to Diversified Communications in 2017. A journalist...

Leave a comment